434 related articles for article (PubMed ID: 19576353)
41. Pharmacological treatment of severe dyslipidaemia in patients with schizophrenia.
Hanssens L; De Hert M; Kalnicka D; van Winkel R; Wampers M; Van Eyck D; Scheen A; Peuskens J
Int Clin Psychopharmacol; 2007 Jan; 22(1):43-9. PubMed ID: 17159459
[TBL] [Abstract][Full Text] [Related]
42. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia.
Maki KC; McKenney JM; Reeves MS; Lubin BC; Dicklin MR
Am J Cardiol; 2008 Aug; 102(4):429-33. PubMed ID: 18678300
[TBL] [Abstract][Full Text] [Related]
43. Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels.
Grover SA; Kaouache M; Joseph L; Barter P; Davignon J
Arch Intern Med; 2009 Oct; 169(19):1775-80. PubMed ID: 19858435
[TBL] [Abstract][Full Text] [Related]
44. Total and acylated ghrelin levels in type 2 diabetic patients: similar levels observed after treatment with metformin, pioglitazone or diet therapy.
Kiyici S; Ersoy C; Oz Gul O; Sarandol E; Demirci M; Tuncel E; Sigirli D; Erturk E; Imamoglu S
Exp Clin Endocrinol Diabetes; 2009 Sep; 117(8):386-90. PubMed ID: 19629933
[TBL] [Abstract][Full Text] [Related]
45. PROactive: time for a critical appraisal.
Betteridge DJ; DeFronzo RA; Chilton RJ
Eur Heart J; 2008 Apr; 29(8):969-83. PubMed ID: 18375395
[TBL] [Abstract][Full Text] [Related]
46. Improved vascular function upon pioglitazone treatment in type 2 diabetes is not associated with changes in mononuclear NF-kappaB binding activity.
Rudofsky G; Reismann P; Grafe IA; Konrade I; Djuric Z; Tafel J; Buchbinder S; Zorn M; Humpert PM; Hamann A; Morcos M; Nawroth PP; Bierhaus A
Horm Metab Res; 2007 Sep; 39(9):665-71. PubMed ID: 17846974
[TBL] [Abstract][Full Text] [Related]
47. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
Khanderia U; Pop-Busui R; Eagle KA
Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
[TBL] [Abstract][Full Text] [Related]
48. Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease.
Teoh H; Mendelsohn AA; Goodman SG; Jaffer S; Chen RY; Tjia S; Theriault L; Langer A; Leiter LA;
Am J Cardiol; 2009 Sep; 104(6):798-804. PubMed ID: 19733714
[TBL] [Abstract][Full Text] [Related]
49. A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome.
Davidson M
Am J Cardiol; 2008 Dec; 102(12A):19L-27L. PubMed ID: 19084086
[TBL] [Abstract][Full Text] [Related]
50. Hypercholesterolemia treatment patterns and low-density lipoprotein cholesterol monitoring in patients with a diagnosis of atherosclerosis in clinical practice.
Davidson MH; Gandhi SK; Ohsfeldt RL; Fox KM
Am J Med; 2009 Jan; 122(1 Suppl):S51-9. PubMed ID: 19110088
[TBL] [Abstract][Full Text] [Related]
51. The clinical implications of the CHICAGO study for the management of cardiovascular risk in patients with type 2 diabetes mellitus.
Polonsky T; Mazzone T; Davidson M
Trends Cardiovasc Med; 2009 Apr; 19(3):94-9. PubMed ID: 19679266
[TBL] [Abstract][Full Text] [Related]
52. Effect of pioglitazone on the drivers of cardiovascular risk in type 2 diabetes.
Donnelly R
Int J Clin Pract; 2007 Jul; 61(7):1160-9. PubMed ID: 17511791
[TBL] [Abstract][Full Text] [Related]
53. Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study.
Nicholls SJ; Tuzcu EM; Wolski K; Bayturan O; Lavoie A; Uno K; Kupfer S; Perez A; Nesto R; Nissen SE
J Am Coll Cardiol; 2011 Jan; 57(2):153-9. PubMed ID: 21211686
[TBL] [Abstract][Full Text] [Related]
54. Paradoxically decreased HDL-cholesterol levels associated with rosiglitazone therapy.
Gutschi LM; Malcolm JC; Favreau CM; Ooi TC
Ann Pharmacother; 2006 Sep; 40(9):1672-6. PubMed ID: 16912247
[TBL] [Abstract][Full Text] [Related]
55. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.
Erdmann E; Dormandy JA; Charbonnel B; Massi-Benedetti M; Moules IK; Skene AM;
J Am Coll Cardiol; 2007 May; 49(17):1772-80. PubMed ID: 17466227
[TBL] [Abstract][Full Text] [Related]
56. Hydroxypropylmethylcellulose lowers cholesterol in statin-treated men and women with primary hypercholesterolemia.
Maki KC; Carson ML; Miller MP; Anderson WH; Turowski M; Reeves MS; Kaden V; Dicklin MR
Eur J Clin Nutr; 2009 Aug; 63(8):1001-7. PubMed ID: 19209184
[TBL] [Abstract][Full Text] [Related]
57. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials.
Mannucci E; Monami M; Lamanna C; Gensini GF; Marchionni N
Diabetes Obes Metab; 2008 Dec; 10(12):1221-38. PubMed ID: 18505403
[TBL] [Abstract][Full Text] [Related]
58. Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: results from two open-label extension studies in hypercholesterolemic patients.
Strony J; Hoffman R; Hanson M; Veltri E
Clin Ther; 2008 Dec; 30(12):2280-97. PubMed ID: 19167588
[TBL] [Abstract][Full Text] [Related]
59. Tacrolimus-induced elevation in plasma triglyceride concentrations after administration to renal transplant patients is partially due to a decrease in lipoprotein lipase activity and plasma concentrations.
Tory R; Sachs-Barrable K; Goshko CB; Hill JS; Wasan KM
Transplantation; 2009 Jul; 88(1):62-8. PubMed ID: 19584682
[TBL] [Abstract][Full Text] [Related]
60. Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein.
Kappelle PJ; Zwang L; Huisman MV; Banga JD; Sluiter WJ; Dallinga-Thie GM; Dullaart RP
Expert Opin Ther Targets; 2009 Jul; 13(7):743-51. PubMed ID: 19505224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
